JP2010509345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509345A5 JP2010509345A5 JP2009536348A JP2009536348A JP2010509345A5 JP 2010509345 A5 JP2010509345 A5 JP 2010509345A5 JP 2009536348 A JP2009536348 A JP 2009536348A JP 2009536348 A JP2009536348 A JP 2009536348A JP 2010509345 A5 JP2010509345 A5 JP 2010509345A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polypeptide
- seq
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 241001465754 Metazoa Species 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000007659 motor function Effects 0.000 claims 2
- 230000007433 nerve pathway Effects 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000010004 neural pathway Effects 0.000 claims 2
- 210000000118 neural pathway Anatomy 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 230000001228 trophic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85802206P | 2006-11-10 | 2006-11-10 | |
| US60/858,022 | 2006-11-10 | ||
| PCT/US2007/023951 WO2008057609A2 (en) | 2006-11-10 | 2007-11-13 | Methods of treating neuronal disorders using mntf peptides and analogs thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509345A JP2010509345A (ja) | 2010-03-25 |
| JP2010509345A5 true JP2010509345A5 (enExample) | 2010-11-11 |
| JP5336384B2 JP5336384B2 (ja) | 2013-11-06 |
Family
ID=39365151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536348A Expired - Fee Related JP5336384B2 (ja) | 2006-11-10 | 2007-11-13 | Ｍｎｔｆペプチドおよびその類似体を用いて神経細胞障害を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8673852B2 (enExample) |
| EP (1) | EP2086331B1 (enExample) |
| JP (1) | JP5336384B2 (enExample) |
| CN (1) | CN101534648B (enExample) |
| AU (1) | AU2007317730B2 (enExample) |
| CA (1) | CA2669658C (enExample) |
| DK (1) | DK2086331T3 (enExample) |
| ES (1) | ES2407454T3 (enExample) |
| WO (1) | WO2008057609A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101951942B (zh) * | 2008-02-21 | 2014-09-03 | 健能万生物制药公司 | Mntf肽组合物及使用方法 |
| MY189079A (en) * | 2009-12-11 | 2022-01-25 | Univ Case Western Reserve | Insulin analogues with chlorinated amino acids |
| GB201015569D0 (en) * | 2010-09-16 | 2010-10-27 | Medical Res Council | Blood assay for prions |
| WO2016210123A1 (en) | 2015-06-26 | 2016-12-29 | Genervon Biopharmaceuticals, LLC | Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease |
| CN110381981A (zh) * | 2016-12-23 | 2019-10-25 | 健能万生物制药公司 | 在诊断和治疗阿尔茨海默病中使用gm6的方法 |
| WO2018129421A1 (en) * | 2017-01-09 | 2018-07-12 | Genervon Biopharmaceuticals, LLC | A promising drug candidate for parkinson's disease |
| MX2020012532A (es) * | 2018-05-31 | 2021-04-28 | Immunity Pharma Ltd | Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841531B2 (en) * | 1996-09-27 | 2005-01-11 | Genervon Biopharmaceuticals Llc | Methods and use of motoneuronotrophic factors |
| US6309877B1 (en) * | 1996-09-27 | 2001-10-30 | Km Biotech, Inc. | Polynucleotides encoding motoneuronotrophic factors |
| DK1587526T3 (da) * | 2003-01-21 | 2012-02-06 | Genervon Biopharmaceuticals Llc | MNTF-peptider og sammensætninger og anvendelsesmåder |
-
2007
- 2007-11-13 AU AU2007317730A patent/AU2007317730B2/en not_active Ceased
- 2007-11-13 WO PCT/US2007/023951 patent/WO2008057609A2/en not_active Ceased
- 2007-11-13 CA CA2669658A patent/CA2669658C/en not_active Expired - Fee Related
- 2007-11-13 JP JP2009536348A patent/JP5336384B2/ja not_active Expired - Fee Related
- 2007-11-13 ES ES07867451T patent/ES2407454T3/es active Active
- 2007-11-13 EP EP07867451A patent/EP2086331B1/en not_active Not-in-force
- 2007-11-13 CN CN2007800419244A patent/CN101534648B/zh not_active Expired - Fee Related
- 2007-11-13 DK DK07867451.2T patent/DK2086331T3/da active
- 2007-11-13 US US11/939,384 patent/US8673852B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509345A5 (enExample) | ||
| JP2012529272A5 (enExample) | ||
| JP2012525844A5 (enExample) | ||
| WO2008057609A4 (en) | Methods of treating neuronal disorders using mntf peptides and analogs thereof | |
| JP2015522576A5 (enExample) | ||
| US20140213512A1 (en) | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 | |
| JP2017502920A5 (enExample) | ||
| JP2010534486A5 (enExample) | ||
| JP2007518818A5 (enExample) | ||
| JP2010505444A5 (enExample) | ||
| JP2009545313A5 (enExample) | ||
| JP2011526886A5 (enExample) | ||
| HRP20220639T1 (hr) | Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe | |
| WO2020067575A1 (en) | Gip receptor agonist peptide compounds and uses thereof | |
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| JP2020509011A (ja) | エリスロポエチン由来ペプチドの細胞損傷防止に対する効果を介した活用 | |
| WO2009121759A3 (en) | Use of pegylated igf-i variants for the treatment of neuromuscular disorders | |
| JP2014510101A5 (enExample) | ||
| RU2011110459A (ru) | Рекомбинантно полученный человеческий фактор viii и ix | |
| JP6529606B2 (ja) | 自己免疫障害及び炎症障害を治療及び／又は予防するための短い合成ペプチド | |
| JP2010513327A5 (enExample) | ||
| JP2019535267A5 (enExample) | ||
| JP2014520764A5 (enExample) | ||
| AU2006310577B2 (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
| RU2009103811A (ru) | Аналоги вазоактивного интестинального пептида |